课题基金 / 基金详情

Novel Synovial Role in Pathogenesis of Gout

Novel Synovial Role in Pathogenesis of Gout
滑膜在痛风发病机制中的新作用
批准号:
9810080
负责人:
Robert A. Terkeltaub
金额:
$18.62万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-01 至 2021-07-31
关键词:
ABCG2 geneADAMTSAcuteAgeAmino Acid Sequence DatabasesAnabolismAreaArthritisAutomobile DrivingBiologicalBiological MarkersBiologyCandidate Disease GeneCellsCharacteristicsChronicClinicalCrystal FormationCrystallizationCustomDNA SequenceDataDefectDepositionDevelopmentDiseaseDropsEnzymesExtracellular MatrixFemaleFibroblastsFlareFrequenciesGenerationsGenetic studyGenomic DNAGenomic Data CommonsGenomicsGlycoproteinsGoutGouty ArthritisHip region structureHyperuricemiaImageInflammationInflammatoryInflammatory ResponseIntegral Membrane ProteinInterleukin-1Interphalangeal joint of toeJointsKnock-outKnowledgeLeadLightLightingLinkLubricantsMediator of activation proteinMetabolic DiseasesMetabolismMinorityMolecular ChaperonesMorbidity - disease rateMucin 1 proteinMucinsMutationNatureO-Glycans Biosynthesis PathwayOutcomePainPalpableParentsPathogenesisPathway interactionsPatientsPeptide HydrolasesPhenotypePlayPolysaccharidesProcessProteomicsPublic HealthPumpQuantitative Trait LociRiskRoleSamplingSerumSmall Interfering RNASpecimenSusceptibility GeneSynovial MembraneSynovitisTestingTherapeuticTissuesToesTransfectionUrateUric AcidVariantWorkarthropathiescell behaviorclinical phenotypeenzyme pathwayexperimental studygenetic approachgenome wide association studyglycoprotein biosynthesisglycoproteomicsglycosylationhigh rewardhigh riskinhibitor/antagonistjoint injuryknock-downlubricinmembernew therapeutic targetnovelnovel markernovel strategiespreventprobandpurine metabolismresponsereverse geneticssialylationsubcutaneoustargeted biomarkerurate transporter

项目摘要

项目成果

Robert A. Terkeltaub的其他基金

相似基金

相关文献

中文摘要
翻译
摘要
英文摘要
Abstract Gout is a highly prevalent disease manifesting most commonly as acute, episodic synovitis that characteristically is excruciatingly painful. Gout continues to grow as a public health problem. The disorder is promoted by elevated body stores of uric acid, and the clinical phenotypes of arthritis are caused by inflammatory responses associated with articular deposits of urate crystals. However, gout develops in only a minority subset of hyperuricemic subjects. Moreover, clinical responses to deposited urate crystals are highly variable, including the frequency and extent of acute arthritis, and progression to palpable subcutaneous tophi, chronic arthritis, and erosive joint damage. There is unmet need to define new therapy targets and biomarkers for incident gout and progression to erosive joint disease. The rationale for this high risk/high reward application is that by clarifying major gaps in knowledge in these areas, the work will be paradigm-shifting, and potentially identify new targets to help prevent and limit gout-associated morbidity. Emerging findings, including from certain arthropathies other than gout, suggest that altered extracellular matrix O-linked glycoprotein components such as the mucin-type boundary lubricant lubricin, and active urate pumping into the joint by an unidentified transport mechanism play a role in development of gout. Our scientific premise is that, in synovial fibroblast lining cells (FLS), mechanistically linked alterations in lubricin and other mucin-type extracellular matrix O-glycoproteins and increased urate secretion are in a mechanistic lop that promotes “common gout”, and progression to chronic, destructive synovitis. We will use primarily a combined candidate gene and reverse genetics approach to analyze a highly unusual observation, specifically a case of gout as an “experiment of nature”. The proband, an otherwise healthy female without hyperuricemia, at age 22 had onset of destructive hip synovitis, and asymmetric acute gouty arthritis flares of small and intermediate joints with classic toe joint gout erosions, and gout definitively confirmed. Collective preliminary data for proband whole genomic DNA, and serum glycomics, proteomics, and glycoproteomics suggest dysregulation in biosynthesis of lubricin and other mucin-type O-glycoproteins that normally serve as constitutive inhibitors of inflammation. Gene candidates are highly enriched in the “reactome” of TMEM171, an incompletely characterized transmembrane molecule implicated in urate transport and recently defined as a gout susceptibility gene. Specifically, the TMEM171 reactome comprises over 20 molecules involved in glycoprotein biosynthesis, more than 10 mucintype. O-glycoproteins, and over 20 ADAMTS protease superfamily members. The work aims to illuminate novel intersections between synovial extracellular matrix biology, urate metabolism and transport, tophus formation, and synovitis. Positive impact includes building a new disease paradigm for “common gout”, potential new biomarkers, and possible gout therapeutics from the novel class of O-glycoprotein agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intersections of matrix biology with inflammation in a new model of gout
  • 批准号:
    10579760
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    Robert A. Terkeltaub
  • 依托单位:
Rheumatic Diseases Research Training Grant
Rheumatic Diseases Research Training Grant
Rheumatic Diseases Research Training Grant
国内基金
海外基金
ADAMTS1靶向MDM2/RBM15/hnRNPC/p16轴诱导心脏衰老的作用机制研究
  • 批准号:
    2026JJ81629
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    蒋路平
  • 依托单位:
肠道菌群色氨酸代谢产物IPA通过NSUN5/ADAMTS-1途径调控胶原降解抑制肺纤维化
  • 批准号:
    2026JJ81748
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    贺兼斌
  • 依托单位:
TGF-β1/SMAD2调节ADAMTS1抑制HDAC6介导心肌梗死后心肌纤维化的机制研究